Tramadol, Alprazolam Racket: ED Arrests Pharma Dealer for Diverting Psychotropic Drugs, Laundering Rs 3.75 Cr

New Delhi: In a major crackdown on drug-linked money laundering, the Enforcement Directorate (ED) has arrested a pharmaceutical businessman accused of siphoning off nearly 75% of his psychotropic drug stock to the black market and generating Rs 3.75 crore in illicit proceeds.

According to a recent media report in the Hindustan times, officials confirmed that the seized evidence exposes a coordinated interstate supply chain involving controlled medicines such as tramadol and alprazolam, diverted far outside legal channels. The accused, Abhishek Kumar, was produced before the special PMLA court in Mohali, where he was remanded to six days of ED custody. Investigators allege that Kumar played a key role in procuring psychotropic drugs and funneling them into illegal distribution networks through his firm.

The ED initiated the money-laundering investigation based on an FIR registered by Punjab Police under relevant sections of the Narcotic Drugs and Psychotropic Substances (NDPS) Act concerning interstate trafficking of psychotropic tablets and capsules, all of which are tightly regulated under Indian law.

In June this year, ED teams carried out searches at 16 premises linked to Abhishek Kumar and his associates. The searches yielded significant documentary and digital evidence pointing to large-scale diversion of controlled substances, unrecorded transactions and undisclosed stock movement.

The probe revealed that various middlemen, retail distributors and wholesalers were sourcing psychotropic medicines from multiple pharmaceutical manufacturers — including Biogenetic Drugs Pvt Ltd, CB Healthcare, Smilax Pharmachem Drug Industries, Aster Pharma and Soul Health Care (I) Pvt Ltd — before diverting them into the illegal trade. These drugs were sold at inflated prices to peddlers, generating substantial profits outside legitimate supply chains.

According to the ED, Abhishek Kumar obtained these medicines in bulk through his firm, Shree Shyam Medical Agency, and then diverted about 75% of the stock to the black market. At this stage of the probe, officials told Hindustan Times that Kumar allegedly inflated legal invoice box counts to disguise differences between actual and recorded stock, enabling him to siphon off drugs illegally and accumulate ₹3.75 crore in proceeds of crime.

The ED stated the investigation is ongoing and forms part of its broader efforts to dismantle drug-trafficking and money-laundering networks operating across state borders.

Related Posts

Supreme Court declines plea to make nucleic acid tests compulsory at blood banks

New Delhi:  The Supreme Court on Friday (March 13, 2026) refused to direct the government to compulsorily conduct “expensive” Nucleic Acid Tests (NAT) to identify diseases ahead of blood transfusions,…

Jaipur: Fraudster Arun Kumar Arrested for Extorting Medical Store Owners by Posing as Drug Inspector

Jaipur— Brahmpuri police in Jaipur have arrested a notorious fraudster who systematically extorted money from medical store owners by impersonating a Drug Inspector. The same accused, Arun Kumar, also cheated…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Supreme Court declines plea to make nucleic acid tests compulsory at blood banks

Supreme Court declines plea to make nucleic acid tests compulsory at blood banks

Jaipur: Fraudster Arun Kumar Arrested for Extorting Medical Store Owners by Posing as Drug Inspector

Jaipur: Fraudster Arun Kumar Arrested for Extorting Medical Store Owners by Posing as Drug Inspector

India’s Medical Devices Sector Logs 4,108 Licensed Manufacturers and ₹20,658 Crore FDI Inflows Since 2018

India’s Medical Devices Sector Logs 4,108 Licensed Manufacturers and ₹20,658 Crore FDI Inflows Since 2018

Abbott introduces its most advanced drug eluting stent XIENCE Skypoint™ in India

Abbott introduces its most advanced drug eluting stent XIENCE Skypoint™ in India

Top 30 pharma companies post 12% revenue growth in first nine months

Top 30 pharma companies post 12% revenue growth in first nine months

India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory

India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory